Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance
By Connor Hart
Shares of Valneva were higher after the company said the European Medicines Agency validated the marketing authorization application for its Lyme disease vaccine candidate.
The stock climbed 26%, to $7.11, in premarket trading Friday. Through Thursday's close, shares have lost more than a third of their value year to date.
The EMA will begin its assessment of the application for the vaccine candidate, PF-07307405, which is being developed with Pfizer, whose shares are flat in premarket trading.
The companies said the application is based on encouraging results from a late-stage trial of the vaccine, which investigated whether the candidate prevented Lyme disease cases in individuals aged five years and older.
The vaccine was well tolerated in the trial, with no safety concerns identified, they added.
"I'm proud of the progress we have made with our Lyme disease vaccine candidate and excited about the opportunity to potentially bring the first vaccine of its kind to Europe," said Annaliesa Anderson, senior VP and chief vaccines officer at Pfizer.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 14, 2026 08:55 ET (12:55 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States